---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042741"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:03:35.549182+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan

## Summary
- Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.
- NDPD holds patents for ProLectin-M (COVID-19, RSV, H1N1, etc.) and a license agreement valued at $8.19M.
- CFO Ola Soderquist adopted 10b5-1 plan to sell up to 500,000 common shares through March 31, 2025.
- Consideration includes 14.1M Bioxytran preferred shares returned to treasury with a $4.0M book value.
- Goodwill of $5.38M recorded; intangible assets amortized over 18 years.

## SEC filing metadata
- accession: 0001493152-24-042741
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315224042741/0001493152-24-042741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315224042741/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042741
- JSON: https://secwatch.observer/filing/0001493152-24-042741.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.